|
Media Releases |
Financial Reports |
Presen-tations |
|
12/27/2007
|
|
|
|
| Lonza sells majority of its shares in Polynt S.p.A. |
Basel, 27.12.2007 – Lonza announces the signing of an agreement to sell approximately 90% (~28,49 million shares) of its holding in Polynt S.p.A. for Euro 3.67 per share to Polimeri Speciali S.r.l., an Italian company indirectly controlled by Investindustrial. Lonza remains shareholder of Polynt with a stake of total 3,39%. After the successful listing of Polynt on the Milan bourse in October 2006 Lonza had kept a minority stake of 31% in Polynt.
“With Investindustrial we have found the right investor for a continued development of Polynt”, comments Lonza CEO Stefan Borgas. “We believe that Polynt will pursue its successful way that it had adopted since the IPO one year ago.”
This transaction represents the final milestone in Lonza’s strategy to focus on its life science operations, following the transformational changes to its portfolio implemented over the last year. Over 90% of Lonza’s sales now relate directly to the life sciences.
This transaction is expected to close after regulatory reviews in the second quarter of 2008.
About Polynt
Polynt Group which Mother company Polynt S.p.A. is headquartered in Scanzorosciate (Bergamo), operates in the niche markets of intermediates for the production of Polymers and is one of the main players in specific sectors, such as those of maleic anhydride and derivatives, phthalic anhydride and general plasticizers, trimellitic anhydride and special plasticizers, unsaturated polyester resins, and thermosetting compounds.
Polynt Group reported in 2006 consolidated revenues of Euro 500.5 million and operates through five legal entities and seven production plants, four of which are located in Italy, one in Germany one in Poland and one in China.
About Investindustrial
Investindustrial is a leading Southern European Industrial and Financial group which provides solutions and capital to Industrial companies principally in Italy and Spain. Its mission is to actively contribute to the development of the companies in which it invests by creating growth opportunities and offering global solutions through an entrepreneurial pan-European Vision.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006, Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.
For further Information:
Head Corporate Communicationsza
Janet White
Tel +41 61 316 8566
Fax +41 61 316 9566
janet.white@lonza.com
Media Relations
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com
Investor Relations
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835
alexandre.pasini@lonza.com
|
|
|
